Clinical Trial Update: ALSENLITE: Senolytics for Alzheimer's Disease [Phase 1, Phase 2]

View source ↗

Summary

ALSENLITE, a senolytic being studied for Alzheimer's disease and Mild Cognitive Impairment, is currently in Phase 1/Phase 2 trials with status listed as ACTIVE_…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Drugs mentioned

• ALSENLITE

Snippet

Sponsor: Mayo Clinic | Conditions: Mild Cognitive Impairment, Alzheimer Disease | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING